Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium
19 Novembro 2021 - 6:05PM
Business Wire
- Ambrx’s abstract of the ongoing ACE-Breast-01
clinical trial for ARX788 was selected for a Spotlight Poster
Discussion –
Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to discover and develop Engineered Precision Biologics
(EPBs), today announced the publication of two abstract poster
presentations to be conducted at the 2021 San Antonio Breast Cancer
Symposium (SABCS), which is being held from December 7-10, 2021.
The abstract poster presentations will highlight clinical data from
Ambrx’s ongoing ACE-Breast-03 and ACE-Breast-01 clinical trials of
ARX788. The company’s ACE-Breast-01 abstract was selected as a
Spotlight Poster Discussion.
All posters will be available virtually on the SABCS website at
www.SABCS.org as well as in the symposium poster hall beginning
Wednesday, December 8, 2021 at 9:00 AM ET. Details on the abstracts
and corresponding poster presentations are shown below.
Poster Number: OT1-02-02 Title:
"A global, phase 2 study of ARX788 in patients with HER2-positive
metastatic breast cancer whose disease is resistant or refractory
to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens”
Presentation Time: December 8, 2021 at 5:00 PM CST
Session Name: Ongoing Trials Poster Session 1
Presenters: Sara Hurvitz, MD; Janice Lu, MD; Joy Yan, MD,
PhD
Spotlight Poster Discussion Number:
PD8-04 Poster Title: “Safety and anti-tumor activity of
ARX788 in HER2-positive metastatic breast cancer patients whose
disease is resistant/refractory to HER2 targeted agents
(trastuzumab, ADCs, TKIs, and bispecific antibodies): ACE-Breast-01
trial results” Presentation Time: December 9, 2021 at 7:00
AM CST Session Name: Spotlight Poster Discussion 8
Presenters: Xichun Hu, MD; Jiang Zhang, MD
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211119005725/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA Ian Stone Managing Director Canale Communications (619)
849-5388 media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Ambrx Biopharma (NYSE:AMAM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024